



ADVANCED
BIONICS

POWERFUL CONNECTIONS

Reliability Report Spring 2021

IMPLANTABLE COCHLEAR STIMULATORS
AND SOUND PROCESSORS



POWERFUL CONNECTIONS START HERE

| | |
|--|----|
| Our Mission | 4 |
| Reporting on Reliability | 5 |
| Implantable Cochlear Stimulators | 6 |
| HiRes Ultra 3D (V2) cochlear implant | 8 |
| HiRes Ultra (V2) cochlear implant | 10 |
| HiRes Ultra 3D (V1) cochlear implant | 12 |
| HiRes Ultra (V1) cochlear implant | 14 |
| HiRes 90K Advantage cochlear implant | 16 |
| HiRes 90K cochlear implant | 18 |
| CII Bionic Ear cochlear implant | 26 |
| Clarion 1.2 cochlear implant | 28 |
| Clarion 1.0 cochlear implant | 30 |
| Sound Processor Stimulators | 32 |
| Naída CI M and Sky CI M sound processors | 32 |
| Naída CI Q90 sound processor | 33 |
| Neptune sound processor | 34 |
| Chorus sound processor | 35 |
| Harmony sound processor | 35 |
| Annex | 36 |

OUR MISSION

Advanced Bionics is proud to have been part of the Sonova Hearing Group for over 10 years, carrying on the Sonova vision of a world where everyone enjoys the delight of hearing and lives a life without limitations. Along with our sister company Phonak, we have strived to bring the latest in hearing instrument technology to our cochlear implant users and professionals.

Our goal is to offer the best hearing performance and to provide reliable and high quality products that exceed your expectations. This reliability report is an example of our commitment to an open and transparent communication to you.

REPORTING ON RELIABILITY

Advanced Bionics remains committed to providing you with clear and accurate information on the quality and reliability of our cochlear implant system.

This report contains information presented in a format that adheres to **ISO 5841-2:2014**¹, the principles outlined in the European Consensus on Cochlear Implant Failures and Explantations² and **ANSI/AAMI CI86 Standard – Cochlear Implant Systems: Requirements for Safety, Functional Verification, Labeling and Reliability Reporting**³. All methodologies are presented for all Cochlear Implant Stimulators (commonly referred to as the implant or device) and the current sound processors.

1. ISO 5841-2 (2014) Implants for Surgery – Cardiac Pacemakers. International Organization for Standardization (ISO), Geneva, Switzerland.

2. European Consensus Statement on Cochlear Implant Failures and Explantations. (2005) *Otology and Neurology*, 26(6): 1097-1099.

3. ANSI/AAMI CI86. Cochlear Implant Systems: Requirements for Safety, Functional Verification, Labeling and Reliability Reporting. (2017). Arlington, VA: American National Standards Institute.

IMPLANTABLE COCHLEAR STIMULATORS

For each implant type and any significant variant of that implant type, there will be a table showing the number of registered users and graphs showing cumulative survival rate. The table will include data for adults, children, and a combined number in accordance with the reporting methodologies.

There will be separate graphs presenting the data in accordance with ISO 5841-2:2014 and ANSI/AAMI CI86 Standard.

Number of registered HiRes 90K Advantage implants

As of March 29, 2021.


Date of first commercial introduction[‡]: 2012

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 15283 | 19937 | 37183 [†] |
| ANSI/AAMI CI86 | 19292* | 17891 | 37183 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

[†] The combined number also includes any registered users for whom we do not have date of birth information.



HIRES 90K ADVANTAGE CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.93% | 99.91% | 99.85% | 99.80% | 99.77% | 99.73% | 99.73% | 99.68% |
| COMBINED | 99.87% | 99.78% | 99.66% | 99.56% | 99.48% | 99.39% | 99.31% | 99.25% |
| CHILDREN | 99.80% | 99.65% | 99.46% | 99.30% | 99.17% | 99.03% | 98.82% | 98.76% |

Detailed CSR percentages are shown for each year in the table. Results are broken up into adults, children, and shown as a combined total.

Graph title shows the implant name and any additional identifying information.

HiRes 90K Advantage

ANSI/AAMI CI86 STANDARD



Cumulative Removal Percentage (CRP) shows the percentage of implants that have been removed after the time in years indicated in the table and on the graph.

CRP values are plotted with a marker for each year. Adults, children, and the combined data are plotted separately

The black vertical bars on each data point are confidence intervals. These are displayed to indicate the accuracy of statistical calculations.

The ANSI/AAMI CI86 Standard requires that all removed devices are classified into three categories, namely those related to device failure, to medical reasons for explant, or those whose reason for explant cannot be determined.

COMBINED ADULT AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.72% | 0.14% | 0.02% | 0.88% | 0.98% | 0.78% |
| 2 | 1.14% | 0.23% | 0.04% | 1.41% | 1.54% | 1.29% |
| 3 | 1.42% | 0.36% | 0.05% | 1.83% | 1.97% | 1.69% |
| 4 | 1.67% | 0.46% | 0.07% | 2.20% | 2.36% | 2.04% |
| 5 | 1.83% | 0.54% | 0.10% | 2.48% | 2.65% | 2.30% |
| 6 | 2.01% | 0.62% | 0.11% | 2.73% | 2.92% | 2.55% |
| 7 | 2.09% | 0.71% | 0.13% | 2.93% | 3.14% | 2.72% |
| 8 | 2.17% | 0.79% | 0.13% | 3.10% | 3.34% | 2.85% |

Detailed CRP values are shown for each year in the table. Results are broken up into adults, children, and shown as a combined total.

Throughout the report, we will present the data and graphs to represent the conditions for: all analysis categories combined; by analysis category for adults and children; removal rates by analysis category for adults; and removal rates by analysis category for children.

Not all data may be shown alongside the graphs due to space limitations. Please see the appendix at the end of the report for a complete data set.


CURRENT-GENERATION IMPLANT DATA

HIRES ULTRA 3D V2

The HiRes™ Ultra 3D (V2) cochlear implant is an update to the previous HiRes Ultra 3D (V1) device. It includes reliability improvements resulting from the Corrective and Preventive Action undertaken by Advanced Bionics related to returned devices showing a common failure mode of fluid ingress into the external electrode pocket.

Based off the standard HiRes Ultra platform but featuring an innovative multi-magnet assembly, the HiRes Ultra 3D implant allows the use of clinical MRI at 1.5T and 3T without the need for magnet removal or head-bandaging. Due to the low torque, the user can be expected to have a hassle free and pain free experience.

The HiRes Ultra 3D (V2) device now has complete 1-year reliability data, and there has not been a confirmed device-related implant failure to date.



Number of registered HiRes Ultra 3D (V2) implants

As of March 29, 2021.

Date of first commercial introduction[‡]: 2019


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 2843 | 1152 | 4255 [†] |
| ANSI/AAMI CI86 | 3282* | 973 | 4255 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

[†] The combined number also includes any registered users for whom we do not have date of birth information.



ISO 5841-2:2014



CUMULATIVE SURVIVAL PERCENTAGE

| Years in use | 1 |
|--------------|---------|
| ADULTS | 100.00% |
| COMBINED | 100.00% |
| CHILDREN | 100.00% |

ANSI/AAMI CI86



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories |
|------|-------------|------------|------------------|----------------------|
| 1 | 0.50% | 0.00% | 0.00% | 0.50% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES ULTRA V2



The HiRes™ Ultra (V2) cochlear implant has the same reliability improvements as the HiRes Ultra 3D (V2) device.

Featuring the proven performance platform as the HiRes 90K™ Advantage, the HiRes Ultra (V2) offers a robust, thin, and discreet mechanical design that is suitable for adults and children.

The HiRes Ultra (V2) device has a limited number of devices that have completed the 1-year data point and the data presented may not reach statistical significance. There has not been a confirmed device-related failure to date.

Number of registered HiRes Ultra (V2) implants

As of March 29, 2021.

Date of first commercial introduction[‡]: 2019


| STANDARD | ADULTS | CHILDREN | COMBINED* |
|-----------------|--------|----------|------------------|
| ISO 5841-2:2014 | 181 | 449 | 802 [†] |
| ANSI/AAMI CI86 | 375* | 427 | 802 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

[†] The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE

| Years in use | Percentage |
|--------------|------------|
| ADULTS | 100.00% |
| COMBINED | 100.00% |
| CHILDREN | 100.00% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories |
|------|-------------|------------|------------------|----------------------|
| 1 | 0.00% | 0.00% | 0.00% | 0.00% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

PREVIOUS-GENERATION IMPLANT DATA

HIRES ULTRA 3D V1

The HiRes™ Ultra 3D (V1) cochlear implant was subject to a Voluntary Field Action initiated by Advanced Bionics on February 18, 2020, and was withdrawn from sale worldwide. This was due to recognition of a common failure mode for a small number of devices, resulting in loss of clinical benefit.

Advanced Bionics will continue to provide regular reliability updates on the HiRes Ultra platform as new data and information becomes available.

Number of registered HiRes Ultra 3D (V1) implants

As of March 29, 2021.

Last year of distribution†: subject to voluntary field action February 18, 2020


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 4539 | 1575 | 6371† |
| ANSI/AAMI CI86 | 5029* | 1342 | 6371 |

‡ Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE

| Years in use | 1 | 1.5 | 2 |
|--------------|--------|--------|--------|
| ADULTS | 99.89% | 99.60% | 98.99% |
| COMBINED | 99.81% | 99.39% | 98.27% |
| CHILDREN | 99.55% | 98.71% | 95.90% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.91% | 0.19% | 0.02% | 1.12% | 1.38% | 0.86% |
| 2 | 1.32% | 1.65% | 0.04% | 3.01% | 3.50% | 2.52% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES ULTRA V1

The HiRes™ Ultra (V1) cochlear implant was subject to a Voluntary Field Action initiated by Advanced Bionics on February 18, 2020, and was withdrawn from sale worldwide. This was due to recognition of a common failure mode for a small number of devices, resulting in loss of clinical benefit.

Advanced Bionics will continue to provide regular reliability updates on the HiRes Ultra platform as new data and information becomes available.

Number of registered HiRes Ultra (V1) implants

As of March 29, 2021.

Last year of distribution†: subject to voluntary field action February 18, 2020


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 7075 | 4263 | 12131† |
| ANSI/AAMI CI86 | 8376* | 3755 | 12131 |

† Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.


† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




ANSI/AAMI CI86


REMOVAL RATES ANALYSIS CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.69% | 0.05% | 0.02% | 0.75% | 0.90% | 0.60% |
| 2 | 1.06% | 0.44% | 0.04% | 1.54% | 1.76% | 1.31% |
| 3 | 1.34% | 2.68% | 0.08% | 4.10% | 4.51% | 3.69% |
| 4 | 1.52% | 7.72% | 0.11% | 9.34% | 10.16% | 8.51% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES 90K ADVANTAGE

The HiRes 90K™ Advantage cochlear implant offers mechanical improvements over its predecessor, the HiRes 90K cochlear implant. It has the capability to offer advanced sound coding strategies, together with the security of a deep bone bed.



Number of registered HiRes 90K Advantage implants

As of March 29, 2021.

Date of first commercial introduction†: 2012. Still available in selected markets.


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 15283 | 19937 | 37183† |
| ANSI/AAMI CI86 | 19292* | 17891 | 37183 |

† Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.93% | 99.91% | 99.85% | 99.80% | 99.77% | 99.73% | 99.73% | 99.68% |
| COMBINED | 99.87% | 99.78% | 99.66% | 99.56% | 99.48% | 99.39% | 99.31% | 99.25% |
| CHILDREN | 99.80% | 99.65% | 99.46% | 99.30% | 99.17% | 99.03% | 98.82% | 98.76% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULT AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.72% | 0.14% | 0.02% | 0.88% | 0.98% | 0.78% |
| 2 | 1.14% | 0.23% | 0.04% | 1.41% | 1.54% | 1.29% |
| 3 | 1.42% | 0.36% | 0.05% | 1.83% | 1.97% | 1.69% |
| 4 | 1.67% | 0.46% | 0.07% | 2.20% | 2.36% | 2.04% |
| 5 | 1.83% | 0.54% | 0.10% | 2.48% | 2.65% | 2.30% |
| 6 | 2.01% | 0.62% | 0.11% | 2.73% | 2.92% | 2.55% |
| 7 | 2.09% | 0.71% | 0.13% | 2.93% | 3.14% | 2.72% |
| 8 | 2.17% | 0.79% | 0.13% | 3.10% | 3.34% | 2.85% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES 90K vendor A post-mod

The HiRes 90K™ cochlear implant offers access to advanced sound coding technologies. It has undergone manufacturing modifications that are listed separately below, with the version currently available being designated as the HiRes 90K (vendor A post-mod) implant.



Number of registered HiRes 90K implants (vendor A post-mod)

As of March 29, 2021.

Last year of distribution†. Still available in selected markets.


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|--------------------|
| ISO 5841-2:2014 | 31417 | 44578 | 78531 [†] |
| ANSI/AAMI CI86 | 39337* | 39194 | 78531 |

[†] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.95% | 99.93% | 99.89% | 99.83% | 99.79% | 99.72% | 99.71% | 99.67% | 99.63% | 99.56% | 99.50% | 99.49% | 99.49% | 99.49% | 99.49% |
| COMBINED | 99.88% | 99.74% | 99.60% | 99.45% | 99.32% | 99.22% | 99.16% | 99.06% | 99.01% | 98.89% | 98.85% | 98.81% | 98.78% | 98.77% | 98.74% |
| CHILDREN | 99.82% | 99.60% | 99.37% | 99.14% | 98.94% | 98.80% | 98.70% | 98.55% | 98.49% | 98.33% | 98.30% | 98.23% | 98.18% | 98.15% | 98.08% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.81% | 0.14% | 0.02% | 0.96% | 1.03% | 0.90% |
| 2 | 1.23% | 0.29% | 0.04% | 1.56% | 1.65% | 1.48% |
| 3 | 1.52% | 0.45% | 0.06% | 2.03% | 2.14% | 1.93% |
| 4 | 1.76% | 0.62% | 0.09% | 2.47% | 2.58% | 2.36% |
| 5 | 1.96% | 0.75% | 0.11% | 2.82% | 2.94% | 2.70% |
| 6 | 2.11% | 0.87% | 0.13% | 3.12% | 3.24% | 2.99% |
| 7 | 2.24% | 0.94% | 0.14% | 3.33% | 3.46% | 3.19% |
| 8 | 2.35% | 1.05% | 0.16% | 3.56% | 3.70% | 3.41% |
| 9 | 2.45% | 1.11% | 0.17% | 3.72% | 3.87% | 3.57% |
| 10 | 2.61% | 1.22% | 0.19% | 4.02% | 4.18% | 3.86% |
| 11 | 2.69% | 1.27% | 0.20% | 4.16% | 4.33% | 3.99% |
| 12 | 2.83% | 1.31% | 0.21% | 4.36% | 4.54% | 4.17% |
| 13 | 2.96% | 1.33% | 0.24% | 4.53% | 4.72% | 4.33% |
| 14 | 3.08% | 1.36% | 0.24% | 4.67% | 4.88% | 4.46% |
| 15 | 3.17% | 1.39% | 0.27% | 4.82% | 5.07% | 4.57% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES 90K vendor A all

Number of registered HiRes 90K implants (vendor A all)

As of March 29, 2021.

Last year of distribution[‡]. Still available in selected markets.


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------------------|----------|--------------------|
| ISO 5841-2:2014 | 32867 | 45672 | 81086 [†] |
| ANSI/AAMI CI86 | 40383 [*] | 39156 | 79539 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

^{*} The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

[†] The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.93% | 99.90% | 99.86% | 99.77% | 99.73% | 99.64% | 99.62% | 99.56% | 99.46% | 99.37% | 99.27% | 99.20% | 99.17% | 99.08% | 98.98% | 98.80% | 98.70% |
| COMBINED | 99.87% | 99.72% | 99.58% | 99.41% | 99.28% | 99.16% | 99.08% | 98.95% | 98.85% | 98.72% | 98.63% | 98.53% | 98.46% | 98.34% | 98.21% | 98.02% | 97.90% |
| CHILDREN | 99.81% | 99.58% | 99.35% | 99.11% | 98.90% | 98.74% | 98.62% | 98.42% | 98.33% | 98.16% | 98.10% | 97.94% | 97.84% | 97.67% | 97.51% | 97.28% | 97.13% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS
CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES
AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.81% | 0.15% | 0.02% | 0.98% | 1.05% | 0.91% |
| 2 | 1.23% | 0.32% | 0.05% | 1.59% | 1.68% | 1.50% |
| 3 | 1.52% | 0.49% | 0.07% | 2.08% | 2.18% | 1.98% |
| 4 | 1.76% | 0.68% | 0.10% | 2.54% | 2.65% | 2.43% |
| 5 | 1.96% | 0.83% | 0.13% | 2.91% | 3.03% | 2.79% |
| 6 | 2.11% | 0.97% | 0.15% | 3.23% | 3.36% | 3.10% |
| 7 | 2.25% | 1.06% | 0.17% | 3.47% | 3.61% | 3.34% |
| 8 | 2.37% | 1.20% | 0.18% | 3.75% | 3.90% | 3.61% |
| 9 | 2.46% | 1.30% | 0.19% | 3.95% | 4.10% | 3.80% |
| 10 | 2.62% | 1.44% | 0.22% | 4.28% | 4.45% | 4.12% |
| 11 | 2.72% | 1.53% | 0.23% | 4.48% | 4.65% | 4.30% |
| 12 | 2.86% | 1.65% | 0.24% | 4.75% | 4.94% | 4.56% |
| 13 | 2.97% | 1.71% | 0.27% | 4.95% | 5.15% | 4.75% |
| 14 | 3.12% | 1.87% | 0.27% | 5.26% | 5.48% | 5.03% |
| 15 | 3.22% | 2.02% | 0.29% | 5.52% | 5.79% | 5.26% |
| 16 | 3.25% | 2.21% | 0.29% | 5.76% | 6.06% | 5.45% |
| 17 | 3.25% | 2.33% | 0.29% | 5.88% | 6.22% | 5.53% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES 90K vendor A pre-mod

Number of registered HiRes 90K implants (vendor A pre-mod)

As of March 29, 2021.

Last year of distribution†: 2005.


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 1450 | 1094 | 2555 [†] |
| ANSI/AAMI CI86 | 1661* | 894 | 2555 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.58% | 99.31% | 99.09% | 98.60% | 98.46% | 98.10% | 97.95% | 97.52% | 96.94% | 96.65% | 96.22% | 95.78% | 95.63% | 95.27% | 95.04% | 94.90% | 94.79% |
| COMBINED | 99.53% | 99.17% | 98.85% | 98.29% | 97.96% | 97.51% | 97.18% | 96.48% | 95.91% | 95.62% | 95.16% | 94.58% | 94.33% | 93.86% | 93.61% | 93.44% | 93.32% |
| CHILDREN | 99.45% | 98.98% | 98.51% | 97.85% | 97.28% | 96.71% | 96.13% | 95.06% | 94.48% | 94.18% | 93.79% | 93.01% | 92.61% | 92.02% | 91.72% | 91.51% | 91.37% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS
CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES
AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.90% | 0.55% | 0.00% | 1.45% | 1.92% | 0.99% |
| 2 | 1.18% | 1.03% | 0.20% | 2.41% | 3.00% | 1.81% |
| 3 | 1.58% | 1.47% | 0.40% | 3.45% | 4.15% | 2.74% |
| 4 | 1.86% | 2.31% | 0.44% | 4.61% | 5.42% | 3.80% |
| 5 | 1.98% | 2.87% | 0.52% | 5.38% | 6.25% | 4.51% |
| 6 | 2.15% | 3.44% | 0.61% | 6.19% | 7.12% | 5.26% |
| 7 | 2.47% | 3.88% | 0.73% | 7.09% | 8.08% | 6.10% |
| 8 | 2.72% | 4.62% | 0.73% | 8.07% | 9.12% | 7.03% |
| 9 | 2.76% | 5.19% | 0.73% | 8.69% | 9.77% | 7.60% |
| 10 | 2.89% | 5.60% | 0.82% | 9.31% | 10.42% | 8.19% |
| 11 | 3.10% | 6.01% | 0.86% | 9.97% | 11.12% | 8.82% |
| 12 | 3.27% | 6.63% | 0.86% | 10.76% | 11.95% | 9.57% |
| 13 | 3.31% | 6.91% | 0.91% | 11.14% | 12.34% | 9.93% |
| 14 | 3.53% | 7.49% | 0.91% | 11.93% | 13.17% | 10.69% |
| 15 | 3.66% | 7.78% | 0.91% | 12.35% | 13.61% | 11.09% |
| 16 | 3.70% | 7.95% | 0.91% | 12.56% | 13.83% | 11.29% |
| 17 | 3.70% | 8.07% | 0.91% | 12.68% | 13.96% | 11.40% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

HIRES 90K vendor B

Number of registered HiRes 90K implants (vendor B)

As of March 29, 2021.

Last year of distribution†. Subject to voluntary recall in 2006.


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|-------------------|
| ISO 5841-2:2014 | 2204 | 1837 | 4065 [†] |
| ANSI/AAMI CI86 | 2561* | 1504 | 4065 |

[‡] Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 97.89% | 91.83% | 87.54% | 83.70% | 80.50% | 78.17% | 75.22% | 73.16% | 71.77% | 70.36% | 69.42% | 68.06% | 67.05% | 66.26% | 65.78% | 65.40% |
| COMBINED | 97.79% | 91.55% | 86.24% | 81.86% | 78.44% | 75.69% | 72.69% | 70.49% | 68.66% | 67.05% | 66.11% | 64.97% | 63.73% | 63.07% | 62.37% | 62.00% |
| CHILDREN | 97.64% | 91.17% | 84.59% | 79.50% | 75.77% | 72.53% | 69.45% | 67.03% | 64.67% | 62.79% | 61.84% | 60.95% | 59.42% | 58.90% | 57.93% | 57.56% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS
CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES
AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.98% | 3.14% | 0.00% | 4.12% | 4.73% | 3.51% |
| 2 | 1.32% | 11.11% | 0.08% | 12.52% | 13.53% | 11.50% |
| 3 | 1.58% | 17.53% | 0.14% | 19.26% | 20.46% | 18.05% |
| 4 | 1.74% | 22.69% | 0.17% | 24.60% | 25.92% | 23.28% |
| 5 | 1.90% | 26.67% | 0.24% | 28.81% | 30.20% | 27.42% |
| 6 | 2.04% | 29.65% | 0.24% | 31.93% | 33.36% | 30.50% |
| 7 | 2.12% | 32.76% | 0.24% | 35.12% | 36.58% | 33.65% |
| 8 | 2.39% | 34.95% | 0.24% | 37.58% | 39.07% | 36.09% |
| 9 | 2.42% | 36.79% | 0.24% | 39.45% | 40.96% | 37.95% |
| 10 | 2.55% | 38.43% | 0.24% | 41.21% | 42.73% | 39.69% |
| 11 | 2.63% | 39.44% | 0.24% | 42.31% | 43.84% | 40.79% |
| 12 | 2.80% | 40.60% | 0.33% | 43.72% | 45.25% | 42.19% |
| 13 | 2.84% | 41.83% | 0.33% | 45.00% | 46.54% | 43.46% |
| 14 | 2.98% | 42.52% | 0.37% | 45.86% | 47.40% | 44.32% |
| 15 | 3.02% | 43.26% | 0.37% | 46.65% | 48.19% | 45.11% |
| 16 | 3.02% | 43.67% | 0.44% | 47.13% | 48.68% | 45.58% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

CII BIONIC EAR

The CII Bionic Ear cochlear implant is the base for the advanced technology found in Advanced Bionics implants today. The platform can still take advantage of the latest innovations today. It benefited from the mechanical improvement made to the earlier C1.2 implants.



Number of registered CII implants

As of March 29, 2021.

Last year of distribution†: 2004


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 3000 | 2084 | 5108† |
| ANSI/AAMI CI86 | 3381* | 1727 | 5108 |

‡ Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE


| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.77% | 99.70% | 99.60% | 99.53% | 99.50% | 99.43% | 99.39% | 99.32% | 99.25% | 99.22% | 99.12% | 99.12% | 99.08% | 99.05% | 99.01% | 98.98% | 98.94% | 98.90% | 98.80% |
| COMBINED | 99.61% | 99.35% | 99.01% | 98.83% | 98.67% | 98.43% | 98.33% | 98.14% | 97.94% | 97.88% | 97.77% | 97.71% | 97.65% | 97.54% | 97.52% | 97.44% | 97.40% | 97.33% | 97.26% |
| CHILDREN | 99.37% | 98.84% | 98.15% | 97.81% | 97.46% | 96.96% | 96.76% | 96.40% | 95.99% | 95.89% | 95.79% | 95.63% | 95.53% | 95.32% | 95.32% | 95.17% | 95.11% | 94.98% | 94.98% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS
CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES
AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULTS AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | CI Up | CI Down |
| 1 | 0.47% | 0.55% | 0.06% | 1.08% | 1.36% | 0.80% |
| 2 | 0.89% | 0.81% | 0.22% | 1.91% | 2.29% | 1.54% |
| 3 | 1.24% | 1.22% | 0.32% | 2.79% | 3.24% | 2.34% |
| 4 | 1.50% | 1.42% | 0.42% | 3.35% | 3.84% | 2.86% |
| 5 | 1.74% | 1.66% | 0.54% | 3.95% | 4.48% | 3.42% |
| 6 | 1.93% | 2.03% | 0.68% | 4.64% | 5.21% | 4.06% |
| 7 | 2.05% | 2.25% | 0.85% | 5.15% | 5.75% | 4.54% |
| 8 | 2.17% | 2.45% | 1.01% | 5.63% | 6.26% | 5.01% |
| 9 | 2.37% | 2.66% | 1.10% | 6.13% | 6.78% | 5.47% |
| 10 | 2.54% | 2.84% | 1.10% | 6.47% | 7.14% | 5.80% |
| 11 | 2.64% | 2.94% | 1.18% | 6.76% | 7.44% | 6.08% |
| 12 | 2.89% | 3.00% | 1.22% | 7.11% | 7.81% | 6.41% |
| 13 | 3.03% | 3.09% | 1.24% | 7.36% | 8.07% | 6.65% |
| 14 | 3.13% | 3.23% | 1.26% | 7.63% | 8.35% | 6.91% |
| 15 | 3.24% | 3.29% | 1.26% | 7.79% | 8.52% | 7.06% |
| 16 | 3.32% | 3.35% | 1.28% | 7.96% | 8.69% | 7.22% |
| 17 | 3.47% | 3.40% | 1.33% | 8.19% | 8.94% | 7.45% |
| 18 | 3.56% | 3.47% | 1.37% | 8.40% | 9.16% | 7.65% |
| 19 | 3.76% | 3.57% | 1.37% | 8.70% | 9.47% | 7.92% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

CLARION 1.2

The Clarion 1.2 (C1.2) implant offers mechanical improvements over its predecessor the C1.0 implant, which first introduced independent current-sources, a key technology differentiator for Advanced Bionics implants.



Number of registered C1.2 implants

As of March 29, 2021.

Last year of distribution†: 2004


| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 4315 | 4149 | 8501† |
| ANSI/AAMI CI86 | 4964* | 3537 | 8501 |

‡ Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

* The adult number also includes users whose personal information is not available or may not be obtainable due to certain privacy laws in certain countries.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014




CUMULATIVE SURVIVAL PERCENTAGE

| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 99.81% | 99.56% | 98.83% | 97.76% | 96.57% | 95.66% | 94.77% | 93.73% | 93.08% | 92.30% | 91.51% | 90.97% |
| COMBINED | 99.42% | 98.72% | 97.36% | 95.75% | 94.10% | 92.51% | 91.34% | 89.93% | 89.01% | 87.94% | 87.09% | 86.49% |
| CHILDREN | 99.00% | 97.83% | 95.80% | 93.61% | 91.46% | 89.14% | 87.66% | 85.83% | 84.63% | 83.24% | 82.30% | 81.63% |


| Years in use | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 90.55% | 90.13% | 89.80% | 89.48% | 89.07% | 88.77% | 88.45% | 88.23% | 88.13% | 87.98% | 87.82% | 87.67% |
| COMBINED | 85.95% | 85.54% | 84.84% | 84.30% | 83.80% | 83.34% | 82.98% | 82.71% | 82.45% | 82.18% | 82.00% | 81.84% |
| CHILDREN | 80.95% | 80.55% | 79.42% | 78.64% | 78.02% | 77.38% | 76.97% | 76.63% | 76.17% | 75.74% | 75.53% | 75.35% |

ANSI/AAMI CI86


REMOVAL RATES ANALYSIS
CATEGORY FOR CHILDREN




REMOVAL RATES ANALYSIS FOR ALL ANALYSIS CATEGORIES
AND DIFFERENT PATIENT POPULATIONS



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULT



REMOVAL RATES ANALYSIS
CATEGORY FOR ADULT AND CHILDREN



COMBINED ADULTS AND CHILDREN

| Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total CI Up | Total CI Down |
|------|-------------|------------|------------------|----------------------|----------------|------------------|
| 1 | 0.36% | 0.97% | 0.13% | 1.45% | 1.71% | 1.20% |
| 2 | 0.50% | 1.80% | 0.24% | 2.54% | 2.87% | 2.20% |
| 3 | 0.68% | 3.26% | 0.41% | 4.35% | 4.78% | 3.92% |
| 4 | 0.88% | 4.98% | 0.58% | 6.45% | 6.97% | 5.93% |
| 5 | 1.07% | 6.67% | 0.84% | 8.58% | 9.17% | 7.99% |
| 6 | 1.37% | 8.34% | 1.01% | 10.72% | 11.37% | 10.07% |
| 7 | 1.57% | 9.65% | 1.17% | 12.38% | 13.08% | 11.69% |
| 8 | 1.80% | 11.24% | 1.38% | 14.42% | 15.16% | 13.68% |
| 9 | 2.01% | 12.22% | 1.66% | 15.89% | 16.66% | 15.12% |
| 10 | 2.25% | 13.46% | 1.99% | 17.70% | 18.50% | 16.90% |
| 11 | 2.46% | 14.36% | 2.21% | 19.03% | 19.85% | 18.20% |
| 12 | 2.72% | 14.93% | 2.44% | 20.09% | 20.94% | 19.25% |
| 13 | 2.97% | 15.49% | 2.57% | 21.03% | 21.88% | 20.17% |
| 14 | 3.22% | 15.97% | 2.67% | 21.86% | 22.73% | 20.99% |
| 15 | 3.59% | 16.70% | 2.80% | 23.09% | 23.97% | 22.20% |
| 16 | 4.08% | 17.28% | 2.97% | 24.33% | 25.23% | 23.43% |
| 17 | 4.57% | 17.83% | 3.18% | 25.58% | 26.50% | 24.67% |
| 18 | 5.45% | 18.29% | 3.31% | 27.05% | 27.98% | 26.12% |
| 19 | 6.22% | 18.67% | 3.42% | 28.31% | 29.25% | 27.37% |
| 20 | 7.10% | 18.92% | 3.56% | 29.58% | 30.54% | 28.62% |
| 21 | 7.60% | 19.17% | 3.69% | 30.46% | 31.43% | 29.48% |
| 22 | 8.21% | 19.51% | 3.82% | 31.54% | 32.54% | 30.54% |
| 23 | 8.85% | 19.69% | 3.87% | 32.41% | 33.45% | 31.37% |
| 24 | 9.77% | 19.85% | 3.97% | 33.59% | 34.73% | 32.45% |

Not all data may be shown alongside the graphs due to space limitations. Please see the **Appendix** at the end of the report for a complete data set.

CLARION 1.0

The Clarion 1.0 (C1.0) implant was Advanced Bionics first device, the start of a technology-forward lineage that continues today. As the number of children implanted with the C1.0 is below the level required for statistical analysis, the data is included with the adult data.



Number of registered C1.0 implants

As of March 29, 2021.


Last year of distribution†: 2004

| STANDARD | ADULTS | CHILDREN | COMBINED |
|-----------------|--------|----------|----------|
| ISO 5841-2:2014 | 316 | 49 | 367† |
| ANSI/AAMI CI86 | - | - | - |

† Dates provided are those for major markets covered by FDA and TUV regulation. Some implants may be pending approval in a subset of additional regions.

† The combined number also includes any registered users for whom we do not have date of birth information.

ISO 5841-2:2014



CUMULATIVE SURVIVAL PERCENTAGE

| Years in use | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 97.78% | 97.47% | 96.19% | 95.56% | 94.28% | 93.32% | 93.32% | 92.68% | 91.72% | 91.39% | 90.42% | 90.42% | 90.42% |
| COMBINED | 98.09% | 96.73% | 95.63% | 95.08% | 93.99% | 92.89% | 92.89% | 92.34% | 91.50% | 91.23% | 90.39% | 90.11% | 89.55% |

| Years in use | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
|--------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ADULTS | 89.77% | 89.11% | 88.45% | 88.12% | 88.12% | 88.12% | 88.12% | 87.78% | 87.44% | 87.11% | 86.42% | 85.72% |
| COMBINED | 88.98% | 88.42% | 87.85% | 87.28% | 87.28% | 87.28% | 87.28% | 87.00% | 86.71% | 86.13% | 85.54% | 84.94% |

ANSI/AAMI CI86

The ANSI/AAMI CI86 Standard does not require reporting for devices older than 20 years after the last implantation of that device type. Please refer to the ISO data for information.

SOUND PROCESSOR STIMULATORS

For each currently-available sound processor, there will be a simple reliability number based on the average global yearly return rate and graphical data in compliance with ANSI/AAMI CI86 Standard that shows the monthly failure rate.

Where possible this monthly data is further categorized into failure mechanisms, if known, to include mechanical, electronic, moisture damage, and other. In specification processors, commonly referred to as no-fault-found, are also included. Where available, the number of registered users is shown, categorized into adult, children, and combined.

NAÍDA CI M AND SKY CI M

The Naída™ CI M sound processor for adults and Sky CI™ M sound processor for children are the newest Advanced Bionics products integrated with the latest advancements from Phonak, the Marvel platform. With built-in connectivity solutions and the ability to automatically sense and adapt to every situation, the Naída CI M and Sky CI M processors are designed to give you the best hearing experience.

As field data becomes available we will present the reliability metrics on these processors in future reports.



NAÍDA CI M


SKY CI M



NAÍDA CI Q90

The Naída CI Q90 sound processor features state-of-the-art technologies exclusively available from Advanced Bionics and Phonak for the best possible hearing experience.

RELIABILITY: 99.51%*



FAILED COMPONENT RETURN RATE[‡]

| Cause | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.16% | 0.15% | 0.14% | 0.13% | 0.19% | 0.27% | 0.23% | 0.20% | 0.22% | 0.11% | 0.15% | 0.15% | 0.15% |
| Moisture | 0.18% | 0.21% | 0.09% | 0.15% | 0.26% | 0.23% | 0.23% | 0.26% | 0.20% | 0.20% | 0.17% | 0.18% | 0.13% |
| Electrical | 0.12% | 0.06% | 0.08% | 0.06% | 0.09% | 0.10% | 0.10% | 0.06% | 0.07% | 0.08% | 0.04% | 0.08% | 0.07% |
| Other | 0.04% | 0.06% | 0.05% | 0.07% | 0.05% | 0.10% | 0.07% | 0.09% | 0.04% | 0.03% | 0.02% | 0.00% | 0.01% |


[‡]The number per month represents the unit that complete failure analysis in that month.

* Reliability is 1 minus the return rate. The return rate is the average global monthly return rate over a 12-month period from February 2020 to February 2021.

NEPTUNE

The Neptune™ sound processor is the first and only swimmable sound processor.

RELIABILITY: 99.74%*



FAILED COMPONENT RETURN RATE‡


| Cause | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.12% | 0.00% | 0.00% | 0.04% | 0.00% | 0.04% | 0.00% | 0.00% | 0.00% | 0.02% | 0.05% | 0.00% | 0.04% |
| Moisture | 0.00% | 0.00% | 0.06% | 0.02% | 0.00% | 0.04% | 0.05% | 0.00% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% |
| Electrical | 0.12% | 0.25% | 0.12% | 0.14% | 0.35% | 0.34% | 0.35% | 0.34% | 0.15% | 0.10% | 0.14% | 0.12% | 0.12% |
| Other | 0.00% | 0.00% | 0.03% | 0.00% | 0.00% | 0.04% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |

*The number per month represents the unit that complete failure analysis in that month.

CHORUS

The Chorus™ sound processor is compatible with C1.0 and C1.2 cochlear implants, and offers integrated Roger™ technology for connectivity and performance.

RELIABILITY: 99.65%*



FAILED COMPONENT RETURN RATE‡

| Cause | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 |
|------------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| Mechanical | 0.00% | 0.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.22% | 0.41% | 0.64% | 0.00% | 0.38% | 0.00% | 0.00% |
| Moisture | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Electrical | 0.35% | 0.00% | 0.16% | 0.15% | 0.44% | 0.13% | 0.43% | 0.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.13% |
| Other | 0.00% | 0.17% | 0.00% | 0.00% | 0.00% | 0.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |

‡The number per month represents the unit that complete failure analysis in that month.

HARMONY

The Harmony™ sound processor is compatible with C1.0 and C1.2 cochlear implants, providing performance-driven technology. Harmony processor is no longer commercially marketed in the United States. It is only provided as an upgrade processor for C1 users, and therefore is out of the scope for the CI86 reporting.

RELIABILITY: 99.83%*

* Reliability is 1 minus the return rate. The return rate is the average global monthly return rate over a 12-month period from February 2020 to February 2021.

STANDARD ANSI/AAMI CI86

HIRES ULTRA 3D V2

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories |
|----------|------|-------------|------------|------------------|----------------------|
| ADULTS | 1 | 0.54% | 0.00% | 0.00% | 0.54% |
| CHILDREN | 1 | 0.36% | 0.00% | 0.00% | 0.36% |

HIRES ULTRA V2

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories |
|----------|------|-------------|------------|------------------|----------------------|
| ADULTS | 1 | 0.00% | 0.00% | 0.00% | 0.00% |
| CHILDREN | 1 | 0.00% | 0.00% | 0.00% | 0.00% |

HIRES ULTRA 3D V1

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.88% | 0.12% | 0.02% | 1.02% | 1.29% | 0.74% |
| | 2 | 1.26% | 0.95% | 0.05% | 2.26% | 2.73% | 1.79% |
| CHILDREN | 1 | 1.05% | 0.45% | 0.00% | 1.50% | 2.15% | 0.85% |
| | 2 | 1.54% | 4.35% | 0.00% | 5.89% | 7.41% | 4.37% |

HIRES ULTRA V1

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.75% | 0.02% | 0.02% | 0.80% | 0.99% | 0.61% |
| | 2 | 1.21% | 0.34% | 0.04% | 1.58% | 1.86% | 1.31% |
| | 3 | 1.53% | 2.17% | 0.07% | 3.78% | 4.24% | 3.31% |
| | 4 | 1.65% | 5.64% | 0.11% | 7.40% | 8.23% | 6.57% |
| CHILDREN | 1 | 0.53% | 0.11% | 0.00% | 0.64% | 0.90% | 0.39% |
| | 2 | 0.72% | 0.67% | 0.03% | 1.43% | 1.83% | 1.03% |
| | 3 | 0.87% | 4.05% | 0.08% | 5.01% | 5.90% | 4.12% |
| | 4 | 1.24% | 13.72% | 0.08% | 15.04% | 17.14% | 12.94% |

HIRES 90K ADVANTAGE

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.68% | 0.07% | 0.02% | 0.76% | 0.89% | 0.64% |
| | 2 | 1.19% | 0.09% | 0.03% | 1.30% | 1.47% | 1.14% |
| | 3 | 1.46% | 0.14% | 0.04% | 1.64% | 1.82% | 1.45% |
| | 4 | 1.74% | 0.17% | 0.04% | 1.96% | 2.16% | 1.76% |
| | 5 | 1.94% | 0.21% | 0.04% | 2.20% | 2.42% | 1.98% |
| | 6 | 2.10% | 0.23% | 0.06% | 2.39% | 2.62% | 2.16% |
| | 7 | 2.21% | 0.23% | 0.07% | 2.51% | 2.76% | 2.26% |
| | 8 | 2.33% | 0.28% | 0.07% | 2.68% | 2.99% | 2.38% |
| CHILDREN | 1 | 0.76% | 0.21% | 0.03% | 1.01% | 1.15% | 0.86% |
| | 2 | 1.09% | 0.40% | 0.05% | 1.53% | 1.72% | 1.35% |
| | 3 | 1.38% | 0.62% | 0.06% | 2.06% | 2.28% | 1.84% |
| | 4 | 1.57% | 0.81% | 0.11% | 2.49% | 2.74% | 2.24% |
| | 5 | 1.68% | 0.95% | 0.19% | 2.82% | 3.09% | 2.54% |
| | 6 | 1.88% | 1.11% | 0.19% | 3.18% | 3.49% | 2.87% |
| | 7 | 1.94% | 1.34% | 0.22% | 3.50% | 3.86% | 3.14% |
| | 8 | 1.94% | 1.49% | 0.22% | 3.65% | 4.06% | 3.23% |

HIRES 90K vendor A post-mod

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.80% | 0.06% | 0.02% | 0.88% | 0.97% | 0.78% |
| | 2 | 1.32% | 0.11% | 0.04% | 1.48% | 1.59% | 1.36% |
| | 3 | 1.64% | 0.16% | 0.06% | 1.86% | 2.00% | 1.73% |
| | 4 | 1.92% | 0.23% | 0.08% | 2.24% | 2.39% | 2.09% |
| | 5 | 2.15% | 0.28% | 0.09% | 2.52% | 2.68% | 2.36% |
| | 6 | 2.30% | 0.35% | 0.12% | 2.77% | 2.94% | 2.60% |
| | 7 | 2.45% | 0.37% | 0.13% | 2.95% | 3.12% | 2.77% |
| | 8 | 2.59% | 0.45% | 0.14% | 3.18% | 3.36% | 2.99% |
| | 9 | 2.68% | 0.48% | 0.14% | 3.31% | 3.50% | 3.11% |
| | 10 | 2.79% | 0.56% | 0.16% | 3.51% | 3.72% | 3.30% |
| | 11 | 2.84% | 0.62% | 0.16% | 3.61% | 3.82% | 3.40% |
| | 12 | 2.96% | 0.63% | 0.16% | 3.74% | 3.97% | 3.52% |
| | 13 | 3.09% | 0.64% | 0.18% | 3.91% | 4.15% | 3.67% |
| | 14 | 3.19% | 0.66% | 0.18% | 4.03% | 4.30% | 3.77% |
| | 15 | 3.29% | 0.66% | 0.18% | 4.13% | 4.42% | 3.84% |
| CHILDREN | 1 | 0.81% | 0.21% | 0.03% | 1.05% | 1.16% | 0.95% |
| | 2 | 1.13% | 0.48% | 0.04% | 1.65% | 1.78% | 1.53% |
| | 3 | 1.39% | 0.76% | 0.06% | 2.21% | 2.36% | 2.06% |
| | 4 | 1.59% | 1.03% | 0.09% | 2.71% | 2.88% | 2.54% |
| | 5 | 1.75% | 1.26% | 0.13% | 3.14% | 3.33% | 2.96% |
| | 6 | 1.90% | 1.45% | 0.15% | 3.49% | 3.69% | 3.30% |
| | 7 | 2.02% | 1.57% | 0.16% | 3.74% | 3.95% | 3.54% |
| | 8 | 2.08% | 1.71% | 0.18% | 3.97% | 4.19% | 3.75% |
| | 9 | 2.19% | 1.80% | 0.19% | 4.18% | 4.41% | 3.95% |
| | 10 | 2.43% | 1.97% | 0.24% | 4.63% | 4.90% | 4.37% |
| | 11 | 2.56% | 2.00% | 0.26% | 4.83% | 5.11% | 4.55% |
| | 12 | 2.73% | 2.11% | 0.29% | 5.13% | 5.44% | 4.82% |
| | 13 | 2.86% | 2.13% | 0.31% | 5.30% | 5.63% | 4.98% |
| | 14 | 3.00% | 2.17% | 0.31% | 5.48% | 5.85% | 5.12% |
| | 15 | 3.09% | 2.25% | 0.40% | 5.74% | 6.19% | 5.28% |

HIRES 90K vendor A all

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|-------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.79% | 0.08% | 0.01% | 0.89% | 0.98% | 0.80% |
| | 2 | 1.31% | 0.14% | 0.05% | 1.50% | 1.62% | 1.38% |
| | 3 | 1.63% | 0.20% | 0.08% | 1.91% | 2.04% | 1.77% |
| | 4 | 1.91% | 0.31% | 0.10% | 2.32% | 2.46% | 2.17% |
| | 5 | 2.13% | 0.37% | 0.11% | 2.61% | 2.77% | 2.45% |
| | 6 | 2.29% | 0.46% | 0.14% | 2.88% | 3.05% | 2.72% |
| | 7 | 2.44% | 0.49% | 0.16% | 3.09% | 3.26% | 2.91% |
| | 8 | 2.58% | 0.61% | 0.16% | 3.35% | 3.54% | 3.16% |
| | 9 | 2.66% | 0.70% | 0.17% | 3.53% | 3.73% | 3.34% |
| | 10 | 2.78% | 0.81% | 0.19% | 3.77% | 3.98% | 3.56% |
| | 11 | 2.83% | 0.90% | 0.19% | 3.92% | 4.14% | 3.70% |
| | 12 | 2.97% | 0.97% | 0.19% | 4.12% | 4.36% | 3.89% |
| | 13 | 3.09% | 1.02% | 0.22% | 4.33% | 4.58% | 4.08% |
| | 14 | 3.24% | 1.15% | 0.22% | 4.61% | 4.89% | 4.33% |
| | 15 | 3.33% | 1.23% | 0.22% | 4.78% | 5.09% | 4.47% |
| | 16 | 3.38% | 1.39% | 0.22% | 4.98% | 5.34% | 4.62% |
| | 17 | 3.38% | 1.47% | 0.22% | 5.07% | 5.47% | 4.67% |
| CHILDREN | 1 | 0.79% | 0.22% | 0.03% | 1.05% | 1.15% | 0.94% |
| | 2 | 1.31% | 0.50% | 0.04% | 1.86% | 1.99% | 1.73% |
| | 3 | 1.63% | 0.79% | 0.07% | 2.49% | 2.64% | 2.34% |
| | 4 | 1.91% | 1.08% | 0.09% | 3.08% | 3.25% | 2.92% |
| | 5 | 2.13% | 1.33% | 0.14% | 3.60% | 3.78% | 3.41% |
| | 6 | 2.29% | 1.54% | 0.15% | 3.98% | 4.17% | 3.78% |
| | 7 | 2.44% | 1.69% | 0.18% | 4.30% | 4.51% | 4.09% |
| | 8 | 2.58% | 1.87% | 0.20% | 4.65% | 4.87% | 4.43% |
| | 9 | 2.66% | 1.98% | 0.21% | 4.85% | 5.09% | 4.62% |
| | 10 | 2.78% | 2.17% | 0.26% | 5.21% | 5.47% | 4.94% |
| | 11 | 2.83% | 2.25% | 0.29% | 5.37% | 5.66% | 5.09% |
| | 12 | 2.97% | 2.45% | 0.32% | 5.74% | 6.06% | 5.43% |
| | 13 | 3.09% | 2.53% | 0.34% | 5.96% | 6.29% | 5.62% |
| | 14 | 3.24% | 2.75% | 0.34% | 6.34% | 6.72% | 5.95% |
| | 15 | 3.33% | 3.01% | 0.39% | 6.72% | 7.20% | 6.25% |
| | 16 | 3.38% | 3.29% | 0.39% | 7.06% | 7.63% | 6.49% |
| | 17 | 3.38% | 3.47% | 0.39% | 7.24% | 7.90% | 6.58% |

HIRES 90K vendor A pre-mod

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|--------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.72% | 0.42% | 0.00% | 1.15% | 1.66% | 0.64% |
| | 2 | 1.03% | 0.85% | 0.24% | 2.12% | 2.81% | 1.43% |
| | 3 | 1.33% | 1.09% | 0.49% | 2.92% | 3.72% | 2.11% |
| | 4 | 1.58% | 1.89% | 0.55% | 4.03% | 4.97% | 3.09% |
| | 5 | 1.70% | 2.33% | 0.62% | 4.64% | 5.65% | 3.64% |
| | 6 | 1.89% | 2.76% | 0.68% | 5.33% | 6.40% | 4.26% |
| | 7 | 2.14% | 3.01% | 0.74% | 5.89% | 7.01% | 4.77% |
| | 8 | 2.20% | 3.57% | 0.74% | 6.51% | 7.69% | 5.34% |
| | 9 | 2.27% | 4.25% | 0.74% | 7.26% | 8.50% | 6.03% |
| | 10 | 2.40% | 4.63% | 0.81% | 7.83% | 9.11% | 6.55% |
| | 11 | 2.52% | 5.01% | 0.81% | 8.34% | 9.65% | 7.02% |
| | 12 | 2.78% | 5.45% | 0.81% | 9.04% | 10.40% | 7.67% |
| | 13 | 2.85% | 5.70% | 0.87% | 9.42% | 10.81% | 8.03% |
| | 14 | 3.17% | 6.14% | 0.87% | 10.19% | 11.63% | 8.75% |
| | 15 | 3.24% | 6.33% | 0.87% | 10.44% | 11.90% | 8.99% |
| | 16 | 3.31% | 6.46% | 0.87% | 10.64% | 12.11% | 9.17% |
| | 17 | 3.31% | 6.55% | 0.87% | 10.73% | 12.20% | 9.25% |

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| CHILDREN | 1 | 1.24% | 0.79% | 0.00% | 2.03% | 2.95% | 1.10% |
| | 2 | 1.46% | 1.36% | 0.12% | 2.94% | 4.04% | 1.83% |
| | 3 | 2.04% | 2.16% | 0.23% | 4.43% | 5.78% | 3.09% |
| | 4 | 2.39% | 3.09% | 0.23% | 5.71% | 7.22% | 4.19% |
| | 5 | 2.50% | 3.90% | 0.35% | 6.75% | 8.39% | 5.12% |
| | 6 | 2.62% | 4.71% | 0.47% | 7.81% | 9.55% | 6.06% |
| | 7 | 3.10% | 5.53% | 0.72% | 9.35% | 11.24% | 7.46% |
| | 8 | 3.71% | 6.59% | 0.72% | 11.01% | 13.04% | 8.98% |
| | 9 | 3.71% | 6.94% | 0.72% | 11.36% | 13.42% | 9.30% |
| | 10 | 3.83% | 7.42% | 0.84% | 12.09% | 14.20% | 9.97% |
| | 11 | 4.20% | 7.89% | 0.97% | 13.06% | 15.24% | 10.88% |
| | 12 | 4.20% | 8.84% | 0.97% | 14.01% | 16.26% | 11.76% |
| | 13 | 4.20% | 9.20% | 0.97% | 14.37% | 16.64% | 12.10% |
| | 14 | 4.20% | 10.04% | 0.97% | 15.21% | 17.53% | 12.88% |
| | 15 | 4.45% | 10.52% | 0.97% | 15.94% | 18.31% | 13.57% |
| | 16 | 4.45% | 10.76% | 0.97% | 16.19% | 18.57% | 13.80% |
| | 17 | 4.45% | 10.94% | 0.97% | 16.36% | 18.77% | 13.96% |

HIRES 90K vendor B

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 1.03% | 3.03% | 0.00% | 4.06% | 4.82% | 3.30% |
| | 2 | 1.33% | 10.84% | 0.09% | 12.25% | 13.52% | 10.99% |
| | 3 | 1.65% | 16.16% | 0.18% | 17.98% | 19.46% | 16.50% |
| | 4 | 1.84% | 20.68% | 0.23% | 22.74% | 24.36% | 21.12% |
| | 5 | 1.94% | 24.29% | 0.28% | 26.51% | 28.21% | 24.80% |
| | 6 | 2.05% | 26.73% | 0.28% | 29.06% | 30.82% | 27.31% |
| | 7 | 2.16% | 29.76% | 0.28% | 32.20% | 34.01% | 30.39% |
| | 8 | 2.45% | 31.65% | 0.28% | 34.38% | 36.22% | 32.54% |
| | 9 | 2.45% | 33.21% | 0.28% | 35.94% | 37.80% | 34.08% |
| | 10 | 2.63% | 34.70% | 0.28% | 37.61% | 39.49% | 35.74% |
| | 11 | 2.63% | 35.66% | 0.28% | 38.57% | 40.46% | 36.68% |
| | 12 | 2.70% | 36.99% | 0.28% | 39.97% | 41.87% | 38.06% |
| | 13 | 2.76% | 38.04% | 0.28% | 41.08% | 42.99% | 39.16% |
| | 14 | 2.90% | 38.83% | 0.28% | 42.01% | 43.93% | 40.09% |
| | 15 | 2.96% | 39.46% | 0.28% | 42.71% | 44.63% | 40.78% |
| | 16 | 2.96% | 39.94% | 0.28% | 43.18% | 45.12% | 41.24% |
| CHILDREN | 1 | 0.88% | 3.34% | 0.00% | 4.22% | 5.24% | 3.21% |
| | 2 | 1.31% | 11.58% | 0.07% | 12.96% | 14.65% | 11.27% |
| | 3 | 1.47% | 19.87% | 0.07% | 21.42% | 23.48% | 19.35% |
| | 4 | 1.56% | 26.10% | 0.07% | 27.74% | 30.00% | 25.48% |
| | 5 | 1.84% | 30.72% | 0.17% | 32.73% | 35.10% | 30.36% |
| | 6 | 2.04% | 34.59% | 0.17% | 36.81% | 39.25% | 34.37% |
| | 7 | 2.04% | 37.85% | 0.17% | 40.07% | 42.55% | 37.58% |
| | 8 | 2.27% | 40.56% | 0.17% | 43.00% | 45.51% | 40.49% |
| | 9 | 2.39% | 42.86% | 0.17% | 45.42% | 47.95% | 42.89% |
| | 10 | 2.39% | 44.75% | 0.17% | 47.30% | 49.84% | 44.77% |
| | 11 | 2.63% | 45.87% | 0.17% | 48.67% | 51.22% | 46.13% |
| | 12 | 3.02% | 46.71% | 0.43% | 50.16% | 52.71% | 47.62% |
| | 13 | 3.02% | 48.27% | 0.43% | 51.72% | 54.26% | 49.17% |
| | 14 | 3.15% | 48.77% | 0.57% | 52.49% | 55.03% | 49.94% |
| | 15 | 3.15% | 49.69% | 0.57% | 53.41% | 55.96% | 50.86% |
| | 16 | 3.15% | 50.00% | 0.77% | 53.92% | 56.47% | 51.36% |

CII BIONIC EAR


| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.47% | 0.39% | 0.03% | 0.89% | 1.21% | 0.57% |
| | 2 | 0.83% | 0.42% | 0.18% | 1.43% | 1.83% | 1.03% |
| | 3 | 1.07% | 0.60% | 0.30% | 1.96% | 2.43% | 1.50% |
| | 4 | 1.37% | 0.66% | 0.39% | 2.41% | 2.93% | 1.90% |
| | 5 | 1.55% | 0.75% | 0.42% | 2.72% | 3.26% | 2.17% |
| | 6 | 1.67% | 0.90% | 0.48% | 3.05% | 3.63% | 2.47% |
| | 7 | 1.79% | 0.96% | 0.66% | 3.41% | 4.02% | 2.80% |
| | 8 | 1.91% | 1.05% | 0.76% | 3.72% | 4.35% | 3.08% |
| | 9 | 2.12% | 1.14% | 0.82% | 4.08% | 4.75% | 3.42% |
| | 10 | 2.27% | 1.20% | 0.82% | 4.30% | 4.98% | 3.62% |
| | 11 | 2.37% | 1.30% | 0.85% | 4.51% | 5.21% | 3.81% |
| | 12 | 2.58% | 1.30% | 0.88% | 4.75% | 5.47% | 4.04% |
| | 13 | 2.64% | 1.36% | 0.88% | 4.88% | 5.60% | 4.15% |
| | 14 | 2.70% | 1.45% | 0.88% | 5.03% | 5.76% | 4.30% |
| | 15 | 2.82% | 1.51% | 0.88% | 5.21% | 5.96% | 4.47% |
| | 16 | 2.88% | 1.57% | 0.88% | 5.34% | 6.09% | 4.58% |
| | 17 | 2.95% | 1.64% | 0.88% | 5.46% | 6.22% | 4.70% |
| | 18 | 3.05% | 1.67% | 0.91% | 5.63% | 6.40% | 4.86% |
| | 19 | 3.14% | 1.76% | 0.91% | 5.82% | 6.61% | 5.03% |
| CHILDREN | 1 | 0.47% | 0.87% | 0.12% | 1.45% | 2.02% | 0.89% |
| | 2 | 1.00% | 1.57% | 0.29% | 2.86% | 3.65% | 2.08% |
| | 3 | 1.59% | 2.46% | 0.35% | 4.40% | 5.37% | 3.44% |
| | 4 | 1.77% | 2.94% | 0.48% | 5.18% | 6.22% | 4.14% |
| | 5 | 2.13% | 3.47% | 0.78% | 6.39% | 7.53% | 5.24% |
| | 6 | 2.44% | 4.25% | 1.09% | 7.79% | 9.04% | 6.53% |
| | 7 | 2.56% | 4.80% | 1.22% | 8.58% | 9.89% | 7.27% |
| | 8 | 2.69% | 5.22% | 1.53% | 9.44% | 10.81% | 8.08% |
| | 9 | 2.87% | 5.65% | 1.66% | 10.18% | 11.60% | 8.77% |
| | 10 | 3.06% | 6.08% | 1.66% | 10.80% | 12.25% | 9.36% |
| | 11 | 3.19% | 6.20% | 1.85% | 11.24% | 12.72% | 9.77% |
| | 12 | 3.51% | 6.39% | 1.92% | 11.81% | 13.31% | 10.31% |
| | 13 | 3.83% | 6.51% | 1.98% | 12.32% | 13.85% | 10.79% |
| | 14 | 4.02% | 6.76% | 2.05% | 12.82% | 14.38% | 11.27% |
| | 15 | 4.08% | 6.82% | 2.05% | 12.95% | 14.51% | 11.39% |
| | 16 | 4.21% | 6.88% | 2.11% | 13.21% | 14.78% | 11.63% |
| | 17 | 4.55% | 6.88% | 2.25% | 13.68% | 15.28% | 12.08% |
| | 18 | 4.62% | 7.03% | 2.33% | 13.99% | 15.60% | 12.37% |
| | 19 | 5.06% | 7.14% | 2.33% | 14.54% | 16.20% | 12.87% |

CLARION 1.2

| | Year | Medical CRP | Device CRP | Inconclusive CRP | Total All Categories | Total | |
|----------|------|-------------|------------|------------------|----------------------|--------|---------|
| | | | | | | CI Up | CI Down |
| ADULTS | 1 | 0.40% | 0.30% | 0.14% | 0.85% | 1.10% | 0.59% |
| | 2 | 0.55% | 0.65% | 0.26% | 1.46% | 1.79% | 1.13% |
| | 3 | 0.75% | 1.39% | 0.41% | 2.54% | 2.98% | 2.11% |
| | 4 | 0.94% | 2.51% | 0.60% | 4.05% | 4.60% | 3.50% |
| | 5 | 1.15% | 3.79% | 0.74% | 5.69% | 6.33% | 5.04% |
| | 6 | 1.41% | 4.83% | 0.83% | 7.06% | 7.77% | 6.35% |
| | 7 | 1.51% | 5.72% | 0.92% | 8.15% | 8.91% | 7.40% |
| | 8 | 1.71% | 6.91% | 1.05% | 9.67% | 10.49% | 8.85% |
| | 9 | 1.84% | 7.62% | 1.21% | 10.67% | 11.52% | 9.82% |
| | 10 | 2.09% | 8.57% | 1.41% | 12.07% | 12.97% | 11.17% |
| | 11 | 2.27% | 9.31% | 1.50% | 13.08% | 14.01% | 12.15% |
| | 12 | 2.55% | 9.82% | 1.71% | 14.08% | 15.03% | 13.12% |
| | 13 | 2.76% | 10.31% | 1.75% | 14.82% | 15.80% | 13.84% |
| | 14 | 2.94% | 10.70% | 1.85% | 15.49% | 16.48% | 14.49% |
| | 15 | 3.22% | 11.13% | 1.92% | 16.27% | 17.29% | 15.26% |
| | 16 | 3.58% | 11.52% | 1.99% | 17.08% | 18.12% | 16.05% |
| | 17 | 4.03% | 11.93% | 2.06% | 18.02% | 19.08% | 16.97% |
| | 18 | 4.78% | 12.29% | 2.09% | 19.15% | 20.23% | 18.07% |
| | 19 | 5.27% | 12.58% | 2.17% | 20.02% | 21.12% | 18.92% |
| | 20 | 5.90% | 12.78% | 2.27% | 20.94% | 22.06% | 19.83% |
| | 21 | 6.27% | 12.95% | 2.34% | 21.56% | 22.69% | 20.42% |
| | 22 | 6.50% | 13.16% | 2.43% | 22.10% | 23.26% | 20.94% |
| | 23 | 7.18% | 13.30% | 2.43% | 22.92% | 24.14% | 21.70% |
| | 24 | 7.74% | 13.44% | 2.43% | 23.61% | 24.93% | 22.29% |
| CHILDREN | 1 | 0.29% | 1.90% | 0.11% | 2.30% | 2.80% | 1.81% |
| | 2 | 0.43% | 3.42% | 0.20% | 4.05% | 4.70% | 3.40% |
| | 3 | 0.58% | 5.89% | 0.41% | 6.88% | 7.71% | 6.05% |
| | 4 | 0.80% | 8.45% | 0.57% | 9.82% | 10.80% | 8.84% |
| | 5 | 0.96% | 10.72% | 0.98% | 12.65% | 13.75% | 11.56% |
| | 6 | 1.32% | 13.29% | 1.28% | 15.89% | 17.08% | 14.69% |
| | 7 | 1.66% | 15.18% | 1.55% | 18.38% | 19.65% | 17.11% |
| | 8 | 1.94% | 17.35% | 1.90% | 21.18% | 22.52% | 19.85% |
| | 9 | 2.29% | 18.70% | 2.36% | 23.36% | 24.74% | 21.97% |
| | 10 | 2.52% | 20.37% | 2.91% | 25.79% | 27.22% | 24.37% |
| | 11 | 2.78% | 21.50% | 3.33% | 27.60% | 29.06% | 26.14% |
| | 12 | 3.01% | 22.18% | 3.59% | 28.78% | 30.25% | 27.30% |
| | 13 | 3.32% | 22.83% | 3.86% | 30.01% | 31.50% | 28.51% |
| | 14 | 3.67% | 23.45% | 3.98% | 31.10% | 32.61% | 29.59% |
| | 15 | 4.19% | 24.62% | 4.22% | 33.02% | 34.56% | 31.49% |
| | 16 | 4.92% | 25.48% | 4.54% | 34.94% | 36.49% | 33.39% |
| | 17 | 5.50% | 26.22% | 5.00% | 36.72% | 38.29% | 35.15% |
| | 18 | 6.60% | 26.85% | 5.30% | 38.76% | 40.34% | 37.17% |
| | 19 | 7.87% | 27.35% | 5.48% | 40.70% | 42.31% | 39.09% |
| | 20 | 9.25% | 27.70% | 5.69% | 42.63% | 44.26% | 41.01% |
| | 21 | 9.97% | 28.08% | 5.94% | 43.99% | 45.64% | 42.34% |
| | 22 | 11.30% | 28.66% | 6.13% | 46.08% | 47.79% | 44.38% |
| | 23 | 11.88% | 28.89% | 6.28% | 47.05% | 48.81% | 45.29% |
| | 24 | 13.48% | 29.11% | 6.56% | 49.16% | 51.13% | 47.18% |

CONTACT US

This report is intended to provide both professionals and our CI wearers with relevant information on the reliability of our products. If you have any questions, please contact us by emailing hear@AdvancedBionics.com or visit [AdvancedBionics.com](https://www.AdvancedBionics.com) for more general information.





🏠 **ADVANCED BIONICS LLC** – 28515 Westinghouse Place - Valencia, CA 91355, United States
T: +1.877.829.0026 - T: +1.661.362.1400 - F: +1.661.362.1500 info.us@advancedbionics.com

EC REP **ADVANCED BIONICS GMBH** - Feodor-Lynen-Strasse 35 – 30625 Hannover, Germany

For information on additional AB locations, please visit advancedbionics.com/contact

Advanced Bionics - A Sonova brand

Please contact your local AB representative for regulatory approval and availability in your region.